Metabolomics-Coupled Functional Pharmacology of Chlorophyll Compounds Isolated From the Leaves of Ficus Exasperata Vahl (Moraceae) Provides Novel Pathways on Myometrial Activity
Restricted accessResearch articleFirst published online June, 2018
Metabolomics-Coupled Functional Pharmacology of Chlorophyll Compounds Isolated From the Leaves of Ficus Exasperata Vahl (Moraceae) Provides Novel Pathways on Myometrial Activity
New chlorophyll derivatives (pheophytins along with pheophorbide derivatives) were isolated from the leaves of Ficus exasperata and were found to have varying effects on uterine contractility. The current study was therefore aimed at the utilization of mass spectrometry and nuclear magnetic resonance spectroscopy coupled with isolated uterine tissue assay as a platform to assist in the determination of the mechanism of activity of the isolated chlorophyll compounds from the plant F exasperata. The pheophytin and pheophorbide compounds (200 µg/mL) were added to the isolated uterine tissues. Mice uteri, treated with the pheophytin compounds, and the physiological buffer in which the uterine tissues were immersed, were rapidly collected and analyzed using high-resolution Fourier transform mass spectrometry and proton (1H) nuclear magnetic resonance for bioinformatics study. Resulting data were analyzed via pairwise chemometric comparison models, with P < .05 considered statistically significant. Primary signaling pathways found to be correlated with the pheophytins in this study included cyclic adenosine monophosphate, dopamine, extracellular signal-regulated kinases 1/2, and glutamate pathways.
BaforEELimCVRowanEGEdrada-EbelR. The leaves of Ficus exasperata Vahl (Moraceae) generates uterine active chemical constituents. J Ethnopharmacol. 2013;145(3):803–812. doi:10.1016/j.jep.2012.12.020.
2.
JamesLP. Metabolomics: integration of a new “omics” with clinical pharmacology. Clin Pharmacol Ther. 2013;94(5):547–551. doi:10.1038/clpt.2013.166.
3.
KellDBGoodacreR. Metabolomics and systems pharmacology: why and how to model the human metabolic network for drug discovery. Drug Discov Today. 2014;19(2):171–182. doi:10.1016/j.drudis.2013.07.014.
4.
GriffinJL. The cinderella story of metabolic profiling: does metabolomics get to go to the functional genomics ball?Philos Trans R Soc Lond B Biol Sci. 2006;361(1465):147–161. doi:10.1098/rstb.2005.1734.
5.
HeijneWHMKienhuisASvan OmmenBStierumRHGrotenJP. Systems toxicology: applications of toxicogenomics, transcriptomics, proteomics and metabolomics in toxicology. Expert Rev Proteomics. 2005;2(5):767–780. doi:10.1586/14789450.2.5.767.
6.
LinCYWuHTjeerdemaRSViantMR. Evaluation of metabolite extraction strategies from tissue samples using NMR metabolomics. Metabolomics. 2007;3:55–67. doi:10.1007/s11306-006-0043-1.
7.
BaforEERowanEGEdrada-EbelR. Towards understanding myometrial regulation: metabolomic investigation reveals possible new pathways of oxytocin and ritodrine activity on the myometrium. Reprod Sci. 2017;24(5):691–705. doi:10.1177/1933719116667224.
8.
CloarecODumasMECraigA. Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic 1H NMR data sets. Anal Chem. 2005;77(5):1282–1289. doi:10.1021/ac048630x.
9.
DoddsKNStaikopoulosVBeckettEA. Uterine contractility in the nonpregnant mouse: changes during the estrous cycle and effects of chloride channel blockade. Biol Reprod. 2015;92(6):141. doi:10.1095/biolreprod.115.129809.
10.
VedernikovYPHartkeJRDe LongMASaadeGRGarfieldRE. Sex hormone effects in non-pregnant rat and human myometrium. Eur J Obstet Gynecol Reprod Biol. 2003;108(1):59–66. doi:10.1016/S0301-2115(02)00415-3.
11.
WraySNobleK. Sex hormones and excitation-contraction coupling in the uterus: the effects of oestrous and hormones. J Neuroendocrinol. 2008:20(4);451–461. doi:10.1111/j.1365-2826.2008.01665.x.
12.
GriffithsALMarshallKMSeniorJFlemingCWoodwardDF. Effect of the oestrous cycle, pregnancy and uterine region on the responsiveness of the isolated mouse uterus to prostaglandin F2α and the thromboxane mimetic U46619. J Endocrinol. 2006;188(3):569–577. doi:10.1677/joe.1.06466.
13.
CibilsLA. Contractility of the nonpregnant human uterus. Obstet Gynecol. 1967;30(3):441–461.
14.
MitzneggPHachBHeimF. Influence of endogenous and exogenous cyclic 3′,5′-AMP on contractile responses induced by oxytocin and calcium in isolated rat uterus. Life Sci. 1970;9(17 pt 1):975–981. doi:10.1016/0024-3205(70)90120-7.
15.
StepienAZiecikAJ. Second messenger systems in the action of LH and oxytocin on porcine endometrial cells in vitro. Theriogenology. 2002;57(9):2217–2227. doi:10.1016/S0093-691X(02)00825-7.
RieszMErdõSL. GABAB receptors in the rabbit uterus may mediate contractile responses. Eur J Pharmacol. 1985;119(3):199–204. doi:10.1016/0014-2999(85)90296-1.
18.
ErdóSL. Identification of GABA receptor binding sites in rat and rabbit uterus. Biochem Biophys Res Commun. 1984;125(1):18–24.
19.
SchmidPCPariaBCKrebsbachRJSchmidHHDeySK. Changes in anandamide levels in mouse uterus are associated with uterine receptivity for embryo implantation. Proc Natl Acad Sci U S A. 1997;94(8):4188–4192. doi:10.1073/pnas.94.8.4188.
20.
PariaBCDasSKDeySK. The preimplantation mouse embryo is a target for cannabinoid ligand-receptor signaling. Proc Natl Acad Sci U S A. 1995;92(21):9460–9464. doi:10.1073/pnas.92.21.9460.
21.
DennedyMCFrielAMHoulihanDDBroderickVMSmithTMorrisonJJ. Cannabinoids and the human uterus during pregnancy. Am J Obstet Gynecol. 2004;190(1):2–9. doi:10.1016/j.ajog.2003.07.013.
22.
DmitrievaNBerkleyKJ. Contrasting effects of WIN 55212-2 on motility of the rat bladder and uterus. J Neurosci. 2002;22(16):7147–7153. doi:20026686.
23.
AsalaAKDiabAAAtiaKIFatthyMA. Cannabinoid induced changes in rat uterine contractility. Zagazig Univ Med J. 2013;19(1):154.
24.
HowlettACMukhopadhyayS. Cellular signal transduction by anandamide and 2-arachidonoylglycerol. Chem Phys Lipids. 2000;108(1-2):53–70. doi:10.1016/S0009-3084(00)00187-0.
25.
BuschLSterin-BordaLBordaE. Expression and biological effects of CB1 cannabinoid receptor in rat parotid gland. Biochem Pharmacol. 2004;68(9):1767–1774. doi:10.1016/j.bcp.2004.06.029.
26.
López-MorenoJAGonzález-CuevasGMorenoGNavarroM. The pharmacology of the endocannabinoid system: functional and structural interactions with other neurotransmitter systems and their repercussions in behavioral addiction. Addict Biol. 2008;13(2):160–187. doi:10.1111/j.1369-1600.2008.00105.x.
27.
EstanLMartinez-MirIRubioEMorales-OlivasFJ. Relaxant effect of dopamine on the isolated rat uterus. Naunyn Schmiedebergs Arch Pharmacol. 1988;338(5):484–488.
28.
CzerskiAZawadskiMCzerskaZ. Influence of dopamine on rat uterine motility in vitro. Acta Vet Brno. 2005;74:9–15.
29.
LalRSharmaPL. Preliminary study on the mechanism of dopamine action on rabbit myometrium. Indian J Med Res. 1983;77:265–270.
30.
SizovPI. Action of GABA-positive preparations on uterus-stimulating effects of activating neuromediators, prostaglandin F2 alpha and oxytocin. Biull Eksp Biol Med. 1992;113(4):387–389.
31.
UrbanJRadwanJLaudańskiTAkerlundM. Dopamine influence on human uterine activity at term pregnancy. Br J Obstet Gynaecol. 1982;89(6):451–455.
32.
ArkinstallSJJonesCT. Regional changes in catecholamine content of the pregnant uterus. J Reprod Fertil. 1985;73(2):547–557. doi:10.1530/jrf.0.0730547.
33.
OttoBSteusloffAJustIAktoriesKPfitzerG. Role of Rho proteins in carbachol-induced contractions in intact and permeabilized guinea-pig intestinal smooth muscle. J Physiol. 1996;496 (pt 2):317–329.
34.
NodaMYasuda-FukazawaCMoriishiK. Involvement of rho in GTP gamma S-induced enhancement of phosphorylation of 20 kDa myosin light chain in vascular smooth muscle cells: inhibition of phosphatase activity. FEBS Lett. 1995;367(3):246–250. doi:0014-5793(95)00573-R [pii].
35.
TaharaMMorishigeKISawadaK. RhoA/Rho-kinase cascade is involved in oxytocin-induced rat uterine contraction. Endocrinology. 2002;143(3):920–929. doi:10.1210/en.143.3.920.
36.
AdamLPFranklinMTRaffGJHathawayDR. Activation of mitogen-activated protein kinase in porcine carotid arteries. Circ Res. 1995;76(2):183–190.
37.
ChildsTJWatsonMHSangheraJSCampbellDLPelechSLMakAS. Phosphorylation of smooth muscle caldesmon by mitogen-activated protein (MAP) kinase and expression of MAP kinase in differentiated smooth muscle cells. J Biol Chem. 1992;267(32):22853–22859.
38.
DessyCKimISougnezCLLaporteRMorganKG. A role for MAP kinase in differentiated smooth muscle contraction evoked by alpha-adrenoceptor stimulation. Am J Physiol. 1998;275(4 pt 1):C1081–C1086.
39.
WattsSW. Serotonin activates the mitogen-activated protein kinase pathway in vascular smooth muscle: use of the mitogen-activated protein kinase kinase inhibitor PD098059. J Pharmacol Exp Ther. 1996;279(3):1541–1550.
40.
LiYJeHDMalekSMorganKG. ERK1/2-mediated phosphorylation of myometrial caldesmon during pregnancy and labor. Am J Physiol Regul Integr Comp Physiol. 2003;284(1):R192–R199. doi:10.1097/00000542-200204001-00115.
41.
NoharaAOhmichiMKoikeK. The role of mitogen-activated protein kinase in oxytocin-induced contraction of uterine smooth muscle in pregnant rat. Biochem Biophys Res Commun. 1996;229(3):938–944. doi:10.1006/bbrc.1996.1905.
42.
OhmichiMKoikeKKimuraA. Role of mitogen-activated protein kinase pathway in prostaglandin F2alpha-induced rat puerperal uterine contraction. Endocrinology. 1997;138(8):3103–3111. doi:10.1210/en.138.8.3103.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
